Plus   Neg

Duke Realty Increases Earnings Guidance - Quick Facts

Duke Realty Corporation (DRE) announced, for fiscal 2018, the company expects FFO, as defined by NAREIT, to a range of $1.33 to $1.39 per diluted share from its previous guidance of $1.29 to $1.37. The company also increased its guidance for growth in same-property net operating income to a range of 4.2 percent to 4.8 percent from the previous range of 3.5 percent to 4.5 percent.

FFO, as defined by NAREIT, was $0.36 per diluted share for the third quarter of 2018, compared to $0.26 per diluted share for the third quarter of 2017. Same-property net operating income growth was 6.3 percent for the three month period ended September 30, 2018 compared to the same period in 2017.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT